Table 4.
Adverse Effects in FPNS and Placebo Armsa
| Second walk test | Third walk test | |||
|---|---|---|---|---|
| Variable | FPNS N (%) |
Placebo N (%) |
FPNS N (%) |
Placebo N (%) |
| Dizziness | 2 (18.2) | 2 (18.2) | 5 (45.5) | 1 (10) |
| Drowsiness | 1 (8.3) | 2 (16.7) | 1 (8.3) | 5 (45.5) |
| Nausea | 0 | 0 | 2 (16.7) | 0 |
| Stuffy nose | 0 | 2 (16.7) | 0 | 0 |
| Runny nose | 0 | 0 | 0 | 0 |
| Itchy nose | 0 | 0 | 0 | 0 |
| Nose Dryness | 0 | 2 (16.7) | 0 | 2 (18.2) |
| Cough | 1 (8.3) | 0 | 0 | 1 (9.1) |
| Sore throat | 0 | 1 (8.3) | 0 | 0 |
| Taste change | 0 | 0 | 0 | 0 |
Abbreviations: FPNS, fentanyl pectin nasal spray
a
Each adverse effect was measured using an 11-point numeric rating scale (0=none, 10=worst) immediate before drug administration and immediately after the walk test (approximately 30 minutes later). The number of patients who reported worsening of adverse effects after drug administration by at least 1 point are shown.